ARAY ACCURAY INC
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1138723 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-12.5%
TTM net income YoY10.0%
TTM EPS YoY22.0%
Revenue 3-yr CAGR-4.6%
Net income 3-yr CAGR—
Margins
Gross margin28.0%
Operating margin-13.1%
Net margin-4.4%
FCF margin-6.9%
EBITDA margin-11.2%
Returns
ROE-30.2%
ROA-4.1%
ROIC (approx.)-32.5%
Asset turnover0.93x
Leverage & solvency
Liabilities / assets86.4%
Debt / equity1.91x
Current ratio1.56x
Interest coverage-1.41x
Cash quality & payout
Operating cash flow / net income1.32x
Accruals ratio1.3%
Payout ratio—
Capex / revenue1.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 | FY20242024-06-30 | FY20232023-06-30 | FY20222022-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $401.95M | $458.50M | $446.55M | $447.61M | $429.91M |
| Cost of revenue | $290.49M | $311.54M | $303.63M | $293.64M | $269.95M |
| Gross profit | $111.45M | $146.97M | $142.92M | $153.96M | $159.96M |
| R&D expense | $37.75M | $47.94M | $49.73M | $57.13M | $57.75M |
| SG&A expense | $45.40M | $47.87M | $50.07M | $48.27M | $44.39M |
| Operating income | -$26.44M | $7.84M | $504,000 | $2.38M | $8.15M |
| Interest expense | $32.91M | $12.95M | $11.62M | $10.63M | $8.13M |
| Pretax income | -$47.25M | $1.13M | -$11.82M | -$6.79M | -$2.00M |
| Income tax | $1.95M | $2.73M | $3.73M | $2.49M | $3.35M |
| Net income | -$49.19M | -$1.59M | -$15.54M | -$9.28M | -$5.35M |
| EBITDA | -$18.50M | $13.99M | $6.41M | $6.91M | $13.66M |
| EPS (basic) | -0.40 | -0.02 | -0.16 | -0.10 | -0.06 |
| EPS (diluted) | — | -0.02 | -0.16 | -0.10 | -0.06 |
| Weighted avg. shares (diluted) | — | 102.77M | 98.27M | 94.88M | 92.09M |
| Banking | |||||
| Provision for credit losses | $573,000 | -$101,000 | -$479,000 | — | — |
| Balance sheet | |||||
| Cash & equivalents | $40.62M | $57.42M | $68.57M | $91.20M | $90.15M |
| Receivables | $67.41M | $83.19M | $92.00M | $74.78M | $94.44M |
| Inventory | $147.07M | $141.02M | $138.32M | $145.15M | $142.25M |
| Current assets | $287.78M | $317.46M | $323.24M | $338.03M | $350.89M |
| PP&E, net | $27.32M | $28.66M | $24.77M | $20.93M | $12.69M |
| Goodwill | $57.91M | $57.80M | $57.67M | $57.68M | $57.84M |
| Intangibles | $0 | $15,000 | $59,000 | $210,000 | $250,000 |
| Total assets | $443.68M | $470.24M | $468.63M | $479.21M | $472.85M |
| Current liabilities | $191.41M | $192.58M | $195.27M | $198.64M | $208.86M |
| Short-term debt | $1.50M | $12.73M | $7.76M | $5.72M | $8.56M |
| Long-term debt | $146.37M | $123.79M | $164.40M | $171.56M | $171.91M |
| Total debt | $147.87M | $136.52M | $172.16M | $177.28M | $180.47M |
| Total liabilities | $401.98M | $389.07M | $423.54M | $425.56M | $419.66M |
| Shareholders' equity | $41.70M | $81.17M | $45.08M | $53.66M | $53.19M |
| Net debt | $107.25M | $79.10M | $103.59M | $86.08M | $90.32M |
| Shares outstanding | 119.43M | 112.64M | 100.19M | 96.53M | 93.50M |
| Cash flow statement | |||||
| Operating cash flow | -$6.98M | $2.86M | -$11.90M | $15.54M | -$2.40M |
| Capital expenditure | $5.86M | $4.27M | $3.60M | $12.61M | $4.72M |
| Free cash flow | -$12.84M | -$1.41M | -$15.51M | $2.92M | -$7.12M |
| Investing cash flow | -$12.28M | -$8.52M | -$3.60M | -$12.68M | -$4.72M |
| Financing cash flow | $6.98M | -$4.25M | -$3.95M | -$2.11M | -$15.37M |
| Depreciation & amortization | $7.94M | $6.15M | $5.91M | $4.53M | $5.51M |
| Stock-based compensation | $6.46M | $10.20M | $9.48M | $10.05M | $10.60M |
| Share buybacks | — | — | — | $0 | $0 |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.